GU Oncology Now spoke with Arlene O. Siefker-Radtke, MD, of the Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, regarding the current and novel targeted therapies entering the market for bladder cancer—in the frontline setting and throughout the treatment continuum—as well as how these agents are being assessed in combination approaches. ...
Expert Interviews
Advertisement
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Preston Sprenkle, MD – Championing Prostate Cancer Diagnostics, Focal Therapy, and Patient Education
Dr. Sprenkle shares his inspiration to practice urologic oncology and his role in popularizing the Artemis Device.Advertisement
